Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 11655305 Treatment of metastatic breast cancer

Patent 11655305 was granted and assigned to Genentech on May, 2023 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity
Is a
Patent
Patent
0
Current Assignee
Genentech
Genentech
0
Date Filed
June 2, 2020
0
Date of Patent
May 23, 2023
0
Patent Applicant
Genentech
Genentech
0
Patent Application Number
16890176
0
Patent Citations
‌
US Patent 7449184 Fixed dosing of HER antibodies
0
‌
US Patent 7468252 Methods for tissue analysis
0
‌
US Patent 7485302 Treatment with anti-ErbB2 antibodies and chemotherapeutic agents
0
‌
US Patent 7498030 Treatment with anti-ErbB2 antibodies and anti-hormonal compounds
0
‌
US Patent 7501122 Treatment with anti-ErbB2 antibody combinations
0
‌
US Patent 7537931 Humanized anti-ERBB2 antibodies and treatment with anti-ERBB2 antibodies
0
‌
US Patent 7575748 Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
0
‌
US Patent 7674589 Methods for tissue analysis
0
‌
US Patent 7682609 Protein formulation
0
‌
US Patent 7700299 Method for predicting the response to a treatment
0
•••
Patent Citations Received
‌
US Patent 11992529 Adjuvant treatment of HER2-positive breast cancer
0
‌
US Patent 12110341 Composition comprising antibody that binds to domain II of HER2 and acidic variants thereof
0
‌
US Patent 12128103 Adjuvant treatment of HER2-positive breast cancer
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
11655305
0
Patent Primary Examiner
‌
Laura B Goddard
0

Find more entities like US Patent 11655305 Treatment of metastatic breast cancer

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.